MaxCyte Q2 Earnings Call Highlights

The brief

MaxCyte reported second-quarter 2026 revenue of $7.3 million, a 15% decrease from $8.5 million in the same period last year. The decline was attributed to lower license revenue and the timing of instrument placements. The company's management stated that the quarter's results exceeded their expectations. MaxCyte's financial performance was impacted by prior-year processing assembly purchases. The company's stock is listed on the NASDAQ under the ticker symbol MXCT.

Auto-summarised from the full article